Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Mycobacterium Tuberculosis Vaccine, Live Attenuated
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Recipient : Biofabri
Deal Size : Inapplicable
Deal Type : Inapplicable
IAVI, Biofabri Start IMAGINE Trial for Tuberculosis Vaccine Candidate MTBVAC
Details : MTBVAC is a live-attenuated vaccine candidate, derived from a human isolate of Mycobacterium tuberculosis. It is being evaluated to prevent active TB lung disease in adolescents and adults.
Product Name : MTBVAC
Product Type : Vaccine
Upfront Cash : Inapplicable
February 26, 2025
Lead Product(s) : Mycobacterium Tuberculosis Vaccine, Live Attenuated
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Recipient : Biofabri
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GRAdHIVNE1 vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Ragon Institute | ReiThera | Mutala Trust
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : GRAdHIVNE1 vaccine is a Vaccine drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of HIV Infections.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
September 27, 2024
Lead Product(s) : GRAdHIVNE1 vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Ragon Institute | ReiThera | Mutala Trust
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MOS1SIP
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Polymun Scientific Immunbiologische Forschung GmbH
Deal Size : Inapplicable
Deal Type : Inapplicable
Mosaic HIV-1 Envelope Trimer Immunogens Administered to People Living with HIV (PLWH) in Africa
Details : MOS1SIP is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of HIV Infections.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
June 07, 2024
Lead Product(s) : MOS1SIP
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Polymun Scientific Immunbiologische Forschung GmbH
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Recipient : HJF Medical Research International
Deal Size : Inapplicable
Deal Type : Inapplicable
Nigeria Hosts First Phase 2 Lassa Fever Vaccine Clinical Trial, Sponsored by IAVI
Details : A vaccine candidate, is being investigated in a phase 2 trial in above 2 years older Nigerian population for the prevention of Lassa fever virus infection.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 04, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Recipient : HJF Medical Research International
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mycobacterium Tuberculosis Vaccine, Live Attenuated
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Bill & Melinda Gates Foundation
Deal Size : $55.0 million
Deal Type : Funding
IAVI and Zendal Announce Funding for Efficacy Trial of Promising TB Vaccine Candidate in Africa
Details : The net proceeds will be used to conduct a Phase IIb trial assessing the safety and efficacy of the tuberculosis (TB) vaccine candidate MTBVAC to prevent active TB lung disease in adolescents and adults.
Product Name : MTBVAC
Product Type : Vaccine
Upfront Cash : Undisclosed
December 18, 2023
Lead Product(s) : Mycobacterium Tuberculosis Vaccine, Live Attenuated
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Bill & Melinda Gates Foundation
Deal Size : $55.0 million
Deal Type : Funding
Lead Product(s) : BG505 SOSIP.664 gp140 Vaccine, Adjuvanted
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : 3M Company | Access to Advanced Health Institute | Polymun Scientific Immunbiologische Forschung GmbH
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BG505 SOSIP.664 gp140 Vaccine, Adjuvanted is a Vaccine drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of HIV Infections.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
August 09, 2023
Lead Product(s) : BG505 SOSIP.664 gp140 Vaccine, Adjuvanted
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : 3M Company | Access to Advanced Health Institute | Polymun Scientific Immunbiologische Forschung GmbH
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mycobacterium Tuberculosis Vaccine, Live Attenuated
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : German Government
Deal Size : $10.0 million
Deal Type : Funding
Germany Issues Award to IAVI to Support Development of the MTBVAC Tuberculosis Vaccine Candidate
Details : The funding will support the late-stage development of MTBVAC, a live, attenuated Mycobacterium tuberculosis vaccine, currently being developed as a potentially longer-lasting TB vaccine for newborns and for the prevention of TB disease in adults and ado...
Product Name : MTBVAC
Product Type : Vaccine
Upfront Cash : Undisclosed
July 07, 2023
Lead Product(s) : Mycobacterium Tuberculosis Vaccine, Live Attenuated
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : German Government
Deal Size : $10.0 million
Deal Type : Funding
Lead Product(s) : rVSV∆G-SEBOV-GP Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : BARDA
Deal Size : Inapplicable
Deal Type : Inapplicable
IAVI Starts First-in-Human Phase I Clinical Trial of Single-Dose Sudan Virus Vaccine Candidate
Details : IAVI C108 (rVSV∆G-SUDV-GP) vaccine candidate for Sudan ebolavirus disease prevention, consisting of replicating vesicular stomatitis vector containing a Sudan ebolavirus glycoprotein immunogen.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
June 27, 2023
Lead Product(s) : rVSV∆G-SEBOV-GP Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : BARDA
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mycobacterium Tuberculosis Vaccine, Live Attenuated
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Recipient : Biofabri
Deal Size : Undisclosed
Deal Type : Agreement
Zendal and IAVI Announce Expanded Agreement to Partner on Development of TB Vaccine Candidate MTBVAC
Details : Under the agreement, IAVI is supporting development, global regulatory strategy, resource mobilization, and access planning for the adolescent/adult tuberculosis (TB) vaccine candidate MTBVAC.
Product Name : MTBVAC
Product Type : Vaccine
Upfront Cash : Undisclosed
May 17, 2023
Lead Product(s) : Mycobacterium Tuberculosis Vaccine, Live Attenuated
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Recipient : Biofabri
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : rVSVΔG-MARV-GP
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : BARDA
Deal Size : $47.0 million
Deal Type : Funding
IAVI and BARDA Expand Partnership to Advance IAVI's Filovirus Vaccine Candidates
Details : The funding will be used in the development and testing of IAVI's single-dose vaccine candidates, rVSVΔG-MARV-GP and rVSVΔG-SUDV-GP, against the filoviruses Marburg virus (MARV) and Sudan ebolavirus (SUDV) respectively.
Product Name : rVSVΔG-MARV-GP
Product Type : Vaccine
Upfront Cash : Undisclosed
March 02, 2023
Lead Product(s) : rVSVΔG-MARV-GP
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : BARDA
Deal Size : $47.0 million
Deal Type : Funding